Teva v Sandoz Presentation Slides
Many have touted the Supreme Court’s January decision in Teva v Sandoz as reversing 20 years of federal practice since Markman v. Westview. What did Teva change? Was the change as substantial as touted? How have practices changed in the months since issuance? This CLE covers what patent prosecutors, litigators, and in-house counsel should consider in view of Teva.
Imron T. Aly
Imron T. Aly serves as co-chair of Schiff Hardin's Pharmaceuticals and Biologics Patent Litigation Team. He focuses his practice in patent infringement and trade secret misappropriation litigation. He has litigated and managed patent infringement and trade secret matters for pharmaceuticals, medical implants and devices, DNA arrays, mechanical production assemblies, computer business methods and financial trading systems.